Relapsing

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the European Commission (EC) has granted approval of BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing…

<!-- Name:DistributionId Value:8799571 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include…

NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot injectable products, announced today…

Ublituximab, an investigational monoclonal antibody targeting CD20, lowered relapse rates relative to teriflunomide (Aubagio) in two identical phase III trials of people with…

NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab,…

Tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, reduced new, active brain lesions in people with relapsing multiple sclerosis (MS), a…

Most patients with morbid obesity and type 2 diabetes (T2D) who underwent weight loss surgery achieved remission from the latter, but relapse was still an issue for some, a…